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Background: Osteoporosis affects over 200 million people worldwide at a high cost to healthcare systems, yet
gaps in management still exist. In response, we developed a multi-component osteoporosis knowledge translation
(Op-KT) tool involving a patient-initiated risk assessment questionnaire (RAQ), which generates individualized
best practice recommendations for physicians and customized education for patients at the point of care. The
objective of this study was to evaluate the effectiveness of the Op-KT tool for appropriate disease management
by physicians.
Methods: The Op-KT tool was evaluated using an interrupted time series design. This involved multiple assessments
of the outcomes 12 months before (baseline) and 12 months after tool implementation (52 data points in total).
Inclusion criteria were family physicians and their patients at risk for osteoporosis (women aged ≥50 years, men
aged ≥65 years). Primary outcomes were the initiation of appropriate osteoporosis screening and treatment.
Analyses included segmented linear regression modeling and analysis of variance.
Results: The Op-KT tool was implemented in three family practices in Ontario, Canada representing 5 family
physicians with 2840 age eligible patients (mean age 67 years; 76% women). Time series regression models showed
an overall increase from baseline in the initiation of screening (3.4%; P < 0.001), any osteoporosis medications (0.5%;
P = 0.006), and calcium or vitamin D (1.2%; P = 0.001). Improvements were also observed at site level for all the three
sites considered, but these results varied across the sites. Of 351 patients who completed the RAQ unprompted
(mean age 64 years, 77% women), the mean time for completing the RAQ was 3.43 minutes, and 56% had any
disease management addressed by their physician. Study limitations included the inherent susceptibility of our
design compared with a randomized trial.
Conclusions: The multicomponent Op-KT tool significantly increased osteoporosis investigations in three
family practices, and highlights its potential to facilitate patient self-management. Next steps include wider
implementation and evaluation of the tool in primary care.
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Over 200 million people worldwide have osteoporosis,
representing a considerable health care and financial
burden [1-6]. The aging of the population will likely
further compound the disease burden [2,3,7]. Fragility
fractures are the clinical consequence of osteoporosis,
with vertebral and hip fractures having the most devas-
tating prognosis [8] and being associated with an in-
creased risk of death [9]. Such fractures can significantly
impair quality of life, physical function, and social
interaction and can lead to admission to long-term care
[10-12]. Clinical practice guidelines are available for
osteoporosis management [13-15], but their implemen-
tation in clinical practice has been inconsistent, such
that many patients are still not receiving appropriate
diagnostic testing or treatment [16-20]. Less than 40%
of patients receive appropriate therapy [17]; and the
proportion of patients with fragility fractures who re-
ceive a diagnostic test or a diagnosis from a physician is
not optimal (range 1.7% – 50%) [18-20]. Knowledge
translation (KT) tools such as clinical decision support
systems may be one solution to closing these practice
gaps because they can provide evidence at the point of
care to facilitate disease management. Clinical decision
support systems generate patient-specific assessments
or recommendations for clinicians by means of software
algorithms that match information from a knowledge da-
tabase to relevant clinical data and provide evidence-based
suggestions for assessment and treatment [21-23].
In response to existing management gaps, we devel-
oped an osteoporosis KT (Op-KT) tool using two theor-
etical frameworks: the knowledge-to-action framework
of Graham et al [24] and the Medical Research Council
(MRC) framework for complex interventions [25]. The
knowledge-to-action framework consists of knowledge
creation (which allows knowledge to be filtered down
from inquiry and synthesis into tools that can aid in deci-
sion making) and a series of iterative and dynamic action
steps to apply this knowledge [24]. Importantly, the frame-
work highlights the need to involve relevant end-users of
the knowledge that is being implemented [24]. The MRC
framework was also considered because it complements
the iterative, phased approach of the knowledge-to-action
framework, and it has the potential to strengthen the de-
velopment and implementation of KT interventions by
addressing challenges to achieving optimal study design,
execution, and generalizability [25]. Our knowledge cre-
ation process involved conducting a systematic review of
randomized controlled trials to determine what features of
osteoporosis tools support clinical decision making [26].
We found that few osteoporosis tools exist, but inter-
ventions consisting of reminders and education targeted
to both physicians and patients had potential for in-
creasing osteoporosis investigations and treatment [26].We combined these findings with available national
osteoporosis guidelines and input from clinicians and
experts in information technology and human-factors
engineering to design a conceptual Op-KT tool. We then
assessed the barriers and facilitators to using this know-
ledge in a qualitative study of focus groups with family
physician [27], which enabled the development of a proto-
type. Finally, we tested the prototype in a mixed-methods
usability study to ensure that it met the needs of target
end-users including patients at risk for osteoporosis and
physicians who provide care for them [28]. A description
of the Op-KT tool is in the Methods below.
The objectives of the current study were to test the
implementability of the multicomponent Op-KT tool and
to determine its effectiveness on appropriate management
of osteoporosis by family physicians (i.e., initiation of inves-
tigations such as bone mineral density testing (BMD) and
treatment with medications such as bisphosphonates and
nutritional supplements such as calcium and vitamin D).
Methods
The tool was implemented between May and November
2009 (phase one) and evaluated between July 2009 and
November 2010 (phase two). Details of the protocol have
been published previously [29]. The study was approved
by the University of Toronto Health Sciences Research
Ethics Board.
Phase one: implementation of the Op-KT tool
Our previous work revealed that, for complex interven-
tions intended for delivery at the point of care, workflow
must be investigated before implementation [27,28]. As
such, we developed an a priori plan involving workflow
analysis to determine the feasibility of physicians and pa-
tients using the tool at the point of care and to identify
factors that would minimize any disruption to usual care
caused by the tool. Our goal was to tailor the tool to the
practice and workflow of each setting and thereby to fa-
cilitate its adoption and uptake during phase two. Imple-
mentation involved observation of clinic staff during the
patient registration process and estimations of the time
patients spent waiting for their physician visit and the
length of visits; an environmental scan to ensure appropri-
ate installation of equipment; development of a custom-
ized procedures manual with input from clinic personnel;
and provision of training to physicians, nurses, and other
clinic staff directly involved in use of the tool. We stag-
gered the schedule for implementing the Op-KT tool for
each of the three sites (approximately two months apart)
to accommodate for the time needed to complete the im-
plementation plan described above (see Figure 1 for study
design and flow). The tool was designed to be pragmatic
(i.e., there was no deliberate procedure to prompt patients
to initiate the RAQ) because workflow analyses indicated
Figure 1 Study design and flow.
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there were some differences between sites in how the
RAQ was initiated and the outputs delivered at the
point of care. For example, the two solo practice sites
had touchscreen devices in the waiting areas (as well as
the examination rooms) to maximize opportunities for
patients to use the tool.
Description of the Op-KT tool
The functional Op-KT tool (accessible at http://knowl-
edgetranslation.ca/osteo_final/) has 3 components:
1. A short (13-item) RAQ that is completed on a
touch-screen device by at-risk patients in the waiting
room or the examination room before their family
physician visit. The RAQ was designed to assess
major and minor osteoporosis risks as outlined in
the Osteoporosis Clinical Practice Guidelines [30].
Screenshots of the RAQ can be viewed in Additional
file 1.
2. A paper-based best practice recommendation
prompt (BestPROMPT), generated according to
patients’ RAQ responses and outlining appropriate,
individualized, guideline-based [30] osteoporosis
management recommendations for family physicians
at the point of care. An example of this is shown in
Additional file 2.
3. A paper-based customized osteoporosis educational
sheet (COPE) given to patients at the end of the
visit, outlining their individual identified risks and
suggestions for managing those risks. An example of
this is shown in Additional file 3.
Setting and population
Three family practices were purposively selected from
the Hamilton Family Health Team, which is the largest
of the 150 approved primary care Family Health Teamsin Ontario, Canada, serving approximately 280 000 people
[31]. It includes a comprehensive team of family phy-
sicians, nurses, registered dieticians, mental health coun-
sellors, psychiatrists, and pharmacists. We selected 3
family practices in total, as this was sufficient to evaluate
the Op-KT tool under different practice settings (one
group and two solo) for a pilot study. Those who agreed
to participate and met the eligibility criteria were included.
Participants were family physicians in solo or group
practice using the PracticeSolutions electronic medical
record (EMR) system (TELUS Health, Canada) and their
patients at risk for osteoporosis (women aged ≥50 years,
men aged ≥65 years). A written consent was obtained
from all participating physicians.
Phase two: evaluation of the Op-KT tool
Study design and sampling
We used the quasi-experimental design with interrupted
time series (ITS) analysis to estimate the effect of the
Op-KT tool on appropriate disease management out-
comes. The study design and its execution were guided
by the ITS quality criteria as outlined by Ramsey et al.
[32] and the Cochrane Effective Practice and Organisa-
tion of Care group [33]. In ITS studies, sample size cal-
culations are related to the estimation of the number of
observations or time points at which data will be col-
lected. The literature is variable on the number of data
points to consider in different situations, but it is gener-
ally recommended that at least 20 pre-intervention and
20 post-intervention observations be used to ensure suf-
ficient power to detect a change and to account for
threats to validity, such as trends, seasonal or cyclical
observations over time, or random fluctuations with no
discernible patterns [32,33]. We used a relatively large
number of data points: 26 data points over the 12 months
before starting the intervention (baseline period) and 26
data points over the 12 months after implementation
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site (see Figure 1). To increase validity, data points were
set closer together (i.e., each data point represented a two-
week period rather than four weeks) [34].
Outcomes
The primary outcomes were initiation of appropriate
osteoporosis investigations (i.e., BMD testing) and treat-
ment (e.g., any bisphosphonate or nutritional supplements
such as calcium and vitamin D) by family physicians.
‘Appropriate’ osteoporosis management was defined ac-
cording to clinical practice guidelines available at the start
of phase two [30]. Screening and treatment recom-
mendations were used to develop a disease management
algorithm [29], which was programmed into the RAQ.
Secondary outcomes were the number of patients who
completed the RAQ (measured by patient-initiated RAQ
logs generated by the touch-screen tablets), the mean time
for completion of the RAQ (minutes), and occurrence of
fractures. We also assessed osteoporosis risk factors by
sex. Using queries in the EMR system and an automated
computer program within the touch-screen devices, we
also documented any actions related to the primary
outcome taken by family physicians of patients who com-
pleted the RAQ and collected site-specific demographic
data (number of patients in practice, number of age-
eligible patients and their mean age, and patients who had
at least one visit during the intervention period).
Unit of analysis and data collection
Our unit of analysis for our primary outcomes was based
on the multiple baseline assessment of individual family
practice sites. These outcomes were first summarized as
rates at each time point, using proportion of osteoporosis
investigation and prescriptions, where the denominator
represented the number of all eligible visits. We established
a stable baseline of standard practice for each site using a
pre-intervention chart review. The specific procedure for
data collection was published in the protocol [29]. Briefly,
two investigators (MK, CM) used patient charts and touch-
screen tablet logs to collect visit-specific data bimonthly.
Every time a patient completed the RAQ, summaries from
physician and patient outputs (BestPROMPT and COPE
sheets, respectively) were saved in a folder on the encrypted
device hard drive. These summaries captured the date and
time the RAQ was initiated and completed and the timed
logs of all RAQ responses. We confirmed RAQ use and
documented any outcome-related actions taken by physi-
cians using chart review. Our unit of analysis for our sec-
ondary outcomes was at the level of patients.
Statistical analysis
We provided site level as well as overall summary mea-
sures, where data was combined across the three sites.For normally distributed continuous data, we reported
means and standard deviations and performed t-tests
and analysis of variance (ANOVA) to compare differences
in means between groups. For non-normally distributed
continuous data, we reported medians and interquartile
ranges and used nonparametric tests for group compari-
sons. For categorical data, we reported frequencies and
percentages and used Fisher exact tests and chi-square
tests for comparing differences between groups.
We used segmented linear regression modeling to exam-
ine the effect of the intervention on the primary outcomes
[35]. This was done at the site level and overall, where rates
of osteoporosis investigations and prescriptions were com-
pared before and after the intervention was introduced;
and combined for the overall estimate by averaging across
all sites. Three primary outcomes considered were: rates
of BMD testing, prescription any osteoporosis medica-
tions, and any nutritional supplements. For each out-
come, the initial segmented regression model used can
be described as:
Y ¼ β0 þ β1timeþ β2Intervention
þβ3timeInterventionþ ε;
Where, Intervention is a dichotomous variable indicat-
ing pre- and post-intervention time periods. The coeffi-
cients β0 and β1 represent the constant term (intercept)
and trend over time (slope) during the baseline (pre-inter-
vention) period, respectively; whereas, β2 and β3 represent
changes in the level and trend of outcomes after the inter-
vention (compared to baseline level and trend).
We used the Durbin-Watson’s test [36] to examine
presence of serial correlation in the residuals after fitting
the segmented regression model. When statistically sig-
nificant autocorrelation is detected, autoregressive inte-
grated moving average (ARIMA) models was used as
required (by including a lag term in the regression models
model, eg. Yt –Yt-1, for first order autocorrelation) using
the Cochrane-Orcutt methodology [37]. All statistical ana-
lyses were conducted using SAS version 9.3, and statistical
significance was set at P < 0.05.
Results
Five family physicians among two solo practices (site one
and site two) and one group practice (site three) partici-
pated in the study. Table 1 shows the patient population
and the number of site visits in the study. Across the three
sites, a total of 9,138 and 9,171 patients visited their phys-
ician during the pre- and post-intervention periods, re-
spectively. Of these, 2390 patients (81% women) were
deemed age eligible (i.e., women ≥50; men ≥65 years of age)
during the pre-intervention period; 2,840 patients (76%
women) were age-eligible during the post-intervention
period (Table 1).
Table 1 Characteristics of the study population across the






Total number of patients in practice 9138 9171
Total number of age-eligible patients* (%) 2,390 (26) 2,840 (31)
Women 1,947 (81) 2,164 (76)
Men 566 (24) 676 (31)
Mean age of patients 67 67
Women 65 65
Men 74 74
Total number of visits (%) 16 283 16 549
Total number of visits by
age-eligible patients† (%)
6,139 (38) 6,306 (38)
*Women ≥50 years of age; men ≥65 years of age.
†Some patients had more than one visit.
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Time series regression models showed an increase in the
initiation of BMD testing from baseline of 2.79% during
pre-intervention time to 6.15% in post-intervention period
(difference of 3.4%, 95% confidence interval [CI 2.03-4.68;
p = <0.001), indicating an increase of 34 BMD tests for
every 1,000 eligible visits across the three sites. Initiation
of any osteoporosis medication increased by 5 in 1,000 eli-
gible visits (difference of 0.5%, CI 0.15-0.85; p = 0.006),
and initiation of any nutritional supplement (calcium or
vitamin D) by 12 in 1000 eligible visits (difference of 1.2%;
CI 0.49-1.91; p = 0.001) (Table 2). Plots of average rates
(averaged over the three sites) for the three outcomes are
shown in Figures 2, 3 and 4, respectively.
A statistically significant autocorrelation of order 7
(correlation value of 0.51, 0.22, 0.34 for BMD testing,Table 2 Results of the interrupted time series analysis for init




Initiation of BMD testing 2.
95% CI 1.
Initiation of any osteoporosis medication‡ 0.
95% CI 0
Initiation of calcium + vitamin D 0.
95% CI 0
Initiation of any nutritional supplement (calcium or vitamin D) 0.
95% CI 0
*BMD, bone mineral density; SD, standard deviation.
†From autoregressive integrated moving-average (ARIMA) model. Intercept only mo
‡The following osteoporosis medications were considered: any bisphosphonate (ale
receptor modulator (e.g., raloxifene), nasal calcitonin, parathyroid hormone, and horany osteoporosis medication and nutritional supplement
with p-values of <0.001, 0.035, 0.004; respectively) was
observed in the residuals; results adjusted for autocorrel-
ation. Further investigation of the residuals (after fitting
the adjusted model) showed randomly distributed resid-
uals indicating no residual serial correlation left between
the measurements across time.
Site-level analysis
Site level interrupted time series analysis indicated that
the intervention led to improvements in outcomes
across all sites, but not all increases were significant.
For example, a statistically significant improvement
was observed for BMD testing (compared to pre-
intervention) in Site 1 (4.29%, CI 1.72-6.86; p = 0.001)
and Site 3 (3.07%, CI 1.55-4.59; p <0.001) but not in Site
2 (3.40%, CI -0.43-7.23; p = 0.082). Increases in osteopor-
osis medication prescriptions in the post- *0intervention
period was also significant in Site 3 (0.78%, CI 0.18-
1.38; p = 0.011) but not in Site 1 (0.18%, CI -0.35-0.71;
p = 0.5023) or Site 2 (0.29%, CI -0.28-0.86, p = 0.3324).
Similarly, the prescription of nutritional supplements
increased across all sites during the post-intervention
period, but this increase was only significant in site
three (1.85%, CI 0.86-2.84; p <0.001). All site level ana-
lyses were adjusted for autocorrelation, when significant
autocorrelations were detected.
The breakdown of the number of eligible visits as well
as the number (and rate) of osteoporosis investigations
and prescriptions by site and combined sites are pro-
vided in Table 3. The results indicate that the median
numbers of visits during the pre- and post-intervention
times were similar for all three sites. Overall, the median
and rate of BMD testing, initiation of osteoporosis medi-
cations and supplements were improved during the post-iation of osteoporosis investigations and treatments,
ean of proportions across the
ree sites (SD)
% Increase P value†
seline Intervention
79 (1.27) 6.15 (2.24) 3.4 <0.001
86 to 3.74 3.38 to 8.42 2.03 to 4.68
42 (0.36) 0.87 (0.66) 0.5 0.006
to 1.13 0 to 2.16 0.15 to 0.85
70 (0.56) 1.58 (0.95) 0.9 <0.001
to 1.80 0 to 3.44 0.39 to 1.41
97 (0.71) 2.13 (1.28) 1.2 0.001
to 2.36 0 to 4.64 0.49 to 1.91
del is fitted since the slopes are not significantly different from zero.
ndronate, etidronate, risedronate, zoledronic acid), any selective estrogen
mone replacement therapy.
Figure 2 Percentage of patients for whom a bone mineral density test was ordered: represented for each site as well as for sites
overall (July 2009 to November 2010). The 52 data points represent 26 two-week segments before and 26 two-week segments after
introduction of the intervention (vertical rule).
Kastner et al. Implementation Science 2014, 9:109 Page 6 of 12
http://www.implementationscience.com/content/9/1/109intervention period compared to the pre-intervention
period, and these findings are consistent across all (Table 3).
For example, the overall rate BMD testing increased during
post-intervention compared to the baseline period by 2.9%,
suggesting that the intervention led to about 29 moreFigure 3 Percentage of patients for whom any osteoporosis medicati
risedronate, or zoledronic acid], selective estrogen receptor modulato
hormone replacement therapy): represented for each site as well as f
represent 26 two-week segments before and 26 two-week segments afterBMD tests for every 1000 eligible visits. The largest in-
crease was observed in Site 3 (i.e., the group practice)
where an increase of 31 BMD tests for every 1,000 eligible
visits were observed. Relatively smaller improvements (but
consistent across all the three sites) were observed for theon was prescribed (bisphosphonates [alendronate, etidronate,
rs [e.g., raloxifene], nasal calcitonin, parathyroid hormone, or
or sites overall (July 2009 to November 2010). The 52 data points
the introduction of the intervention (vertical rule).
Figure 4 Percentage of patients for whom any nutritional supplement (i.e., calcium or vitamin D) was prescribed: represented for each
site as well as for sites overall (July 2009 to November 2010). The 52 data points represent 26 two-week segments before and 26 two-week
segments after the introduction of the intervention (vertical rule).
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plements (Table 3).
Secondary outcomes—patient-level analysis
The RAQ was completed by 351 patients (mean age 64
years; range, 50-90 years; 77% women), who represented
16% of age-eligible patients with at least one physician
visit during the intervention period (Table 4). The mean
time to complete the RAQ was 3.43 minutes (range,
1.32-8.01 minutes). Of those who completed the RAQ,
276 patients (79%) had at least one major risk factor for
osteoporosis (e.g., vertebral compression fracture, family
history of maternal hip fracture) or two minor risk fac-
tors (e.g., rheumatoid arthritis, smoker, weight <57 kg);
in addition, 204 patients (58%) had a previous BMD test
(evenly distributed between those who had the test more
than two years ago and less than two years ago), and 147
patients (42%) had never had a BMD test. More men than
women indicated never having a BMD test (71% vs 33%,
p <0.001). Thirty-two patients (9%) reported already tak-
ing an osteoporosis medication such as a bisphosphonate
(6%), hormone replacement therapy (5%), or selective es-
trogen reuptake modulator (0.3%); and 233 patients (66%)
reported already taking calcium (8%), vitamin D (15%), or
both (43%). There was a significant difference between
men and women for mean age and osteoporosis risk
(p <0.001 for both), but this was expected as the age-
eligibility criterion for men (i.e., age ≥ 65 years) was also
considered a major risk factor for osteoporosis. A total
of 195 patients (56%) had any disease managementaddressed by their physician in response to the tool at
the point of care (N = 86) or within three months of the
RAQ visit (N = 109). We did not analyze fractures be-
cause the incidence across sites was too low to calculate
a clinically meaningful difference between the baseline
and intervention periods (i.e., six versus three fractures,
respectively).
Discussion
This study showed that a multicomponent Op-KT tool
incorporating all disease management components (assess-
ment, diagnosis and treatment) is feasible for use at the
point of care. Use of the tool increased the initiation of
BMD testing and treatment with medications such as
bisphosphonates and vitamin D for patients at risk for
osteoporosis. Our findings are consistent with other studies
investigating osteoporosis disease management [38-40].
However, they also highlight continuing gaps: specifically,
42% of at-risk patients who completed the RAQ reported
never having had a BMD test, and the rate of osteoporosis
investigations was significantly lower among men than
women (consistent with other reports [18,41]). Persist-
ence of these gaps may be explained, in part, by how
interventions are designed to overcome them. Few
osteoporosis interventions include all components of
disease management. Our previous systematic review
found interventions with different combinations of
disease management recommendations in the form of
reminders and education (electronic, paper-based, or
counseling-based), but none addressed all three aspects
Table 3 Number of eligible visits, and number of visits leading to a primary outcome (BMD testing, initiation of osteoporosis medications and nutritional
supplements) across the three sites*
Site Eligible visits BMD testing Initiation of any osteoporosis medication Initiation of any nutritional supplements
(calcium, vitamin D)
Median (IQR) Total Median (IQR) Total Rate‡ (95% CI) Median (IQR) Total Rate (95% CI) Median (IQR) Total Rate (95% CI)
Combined†
Overall 240.0 (51.75) 12,445 10.00 (7.00) 550 4.42 (4.07-4.80) 1.00 (2.00) 82 0.66 (0.53-0.82) 3.00 (3.75) 191 1.53 (1.32-1.77)
Pre-Intervention 238.0 (49.75) 6,139 7.00 (5.25) 180 2.93 (2.53-3.39) 1.00 (1.00) 25 0.41 (0.27-0.61) 2.00 (2.25) 60 0.98 (0.75-1.27)
Post-Intervention 247.0 (60.50) 6,306 14.00 (16.25) 370 5.87 (5.31-6.48) 2.00 (2.25) 57 0.90 (0.69-1.17) 4.50 (4.25) 131 2.08 (1.75-2.47)
Site One
Overall 72.50 (25.50) 3,683 3.00 (3.00) 189 5.13 (4.45-5.91) 0.00 (1.00) 21 0.57 (0.36-0.89) 0.00 (0.00) 14 0.38 (0.21-0.65)
Pre-Intervention 69.0 (23.50) 1,852 2.00 (3.00) 68 3.67 (2.88-4.66) 0.00 (1.00) 9 0.49 (0.24-0.96) 0.00 (0.00) 4 0.22 (0.07-0.59)
Post-Intervention 76.50 (30.75) 1,831 4.50 (3.25) 121 6.61 (5.53-7.87) 0.00 (1.00) 12 0.66 (0.36-1.18) 0.00 (1.00) 10 0.55 (0.28-1.04)
Site Two
Overall 53.50 (15.75) 2,618 1.50 (2.00) 123 4.70 (3.93-5.60) 0.00 (1.00) 20 0.76 (0.48-1.20) 2.00 (2.00) 94 3.59 (2.93-4.39)
Pre-Intervention 52.50 (19.25) 1,219 1.00 (2.00) 40 3.28 (2.38-4.48) 0.00 (1.00) 8 0.66 (0.31-1.34) 1.00 (2.00) 38 3.12 (2.24-4.30)
Post-Intervention 57.00 (19.50) 1,399 2.50 (3.00) 83 5.93 (4.78-7.33) 0.00 (1.00) 12 0.86 (0.47-1.54) 2.00 (3.00) 56 4.00 (3.06-5.20)
Site Three
Overall 114.50 (28.00) 6,144 4.00 (4.25) 238 3.87 (3.41-4.39) 0.00 (1.00) 41 0.67 (0.49-0.91) 1.00 (3.00) 83 1.35 (1.08-1.68)
Pre-Intervention 114.00 (31.00) 3,068 2.00 (3.00) 72 2.34 (1.85-2.96) 0.00 (1.00) 8 0.26 (0.12-0.54) 0.00 (1.00) 18 0.59 (0.36-0.95)
Post-Intervention 117.50 (31.75) 3,076 5.50 (5.00) 166 5.40 (4.64-6.27) 1.00 (1.25) 33 1.07 (0.75-1.52) 2.00 (3.00) 65 2.11 (1.65-2.70)
*BMD = bone mineral density; IQR = interquartile range; CI = confidence interval.
†Combined across the three sites.



















Table 4 Characteristics of patients who completed the risk assessment questionnaire (n = 351)*
Characteristics Site 1 Site 2 Site 3 Combined
Sites
P value†
Between sites Between women
and men
No. (%) of patients‡ 110 (21) 124 (21) 117 (11) 351 (16) NA
Women 81 (74) 93 (75) 98 (84) 272 (77) 0.13 NA
Men 29 (26) 31 (25) 19 (16) 79 (23)
Age, mean (SD), y 64 (9.56) 64 (10.40) 64 (10.55) 64 (10.2) 0.88 <0.001
Age range, y 50-87 50-90 50-89 50-90 NA
Time to complete RAQ, mean (SD), min 3.26 (1.05) 3.42 (1.29) 3.60 (1.28) 3.43 0.08 0.37
Range of completion time, mean, min 1.32-7.93 1.37-8.01 1.37-7.38 1.32-8.01 NA
Number of visits, mean (SD) 3.29 (1.95) 2.37 (1.85) 3.25 (3.14) 2.95 (2.4) 0.004 0.88
Range§ 0-10 0-9 0-25 0-25 NA
Number (%) of patients who had a BMD test
Over 2 y ago 39 (35) 38 (31) 24 (21) 101 (29) 0.03 <0.001
Less than 2 y ago 38 (35) 30 (24) 35 (30) 103 (29) 0.22 0.005
Never 33 (30) 56 (45) 58 (50) 147 (42) 0.008 <0.001
Number (%) of patients at risk for osteoporosis¶ 88 (80) 97 (78) 91 (78) 276 (79) 0.91 <0.001
Number (%) of patients already receiving therapy
Osteoporosis medications 8 (7) 13 (10) 11 (9) 32 (9) 0.69 0.02
Any supplement (calcium or vitamin D) 71 (65) 81 (65) 81 (69) 233 (66) 0.72 <0.001
*All data based on Risk Assessment Questionnaire (RAQ) inputs; SD = standard deviation; BMD = bone mineral density; NA = not applicable.
†Based on analysis of variance or chi-square tests.
‡Percentage calculated as the number of age-eligible patients who completed the RAQ divided by the number of age-eligible patients with at least 1 physician
visit. All percentages in subsequent rows calculated with respect to the number of age-eligible patients who completed the RAQ at the particular site.
§The lower limit of the range is 0 because some patients completed the RAQ during a ‘non-visit’ (i.e., visited the practice but did not see a physician or nurse).
¶At-risk for osteoporosis is defined as 1 major or 2 minor risk factors according to clinical practice guidelines [30].
Kastner et al. Implementation Science 2014, 9:109 Page 9 of 12
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do address disease management completely have been
developed for high-risk [38] and postfracture [41] pa-
tients, but they don’t address how these tools might be
implemented over the long term or how they might be
sustainable. Furthermore, few of the existing tools use a
computer-based platform for decision support [42], most
are not designed to deliver evidence-based messages at
the point of care, and none consider mechanisms to avoid
disruption to usual practice (which can facilitate sus-
tainability). Most tools involve coordinator-based systems
(where dedicated case managers such as nurses, ortho-
pedic surgeons, or other allied healthcare professionals are
involved in facilitating care [38,39,43,44]), use telephone-
based reminders [40,45], or provide reminders or educa-
tion to physicians and patients through a paper-based
[46,47] or counseling-based [48] strategy. These interven-
tions can be resource intensive and therefore may not be
sustainable.
Our study met the clinical goal of the osteoporosis
tool, which was to increase osteoporosis investigations and
treatment. Although the improvements in disease manage-
ment were modest, they represent significant change in the
right direction. Furthermore, the impact was relevant be-
cause the Op-KT tool was not tested under controlledconditions. It was designed and implemented as a prag-
matic tool, so for example, the observed 3.2% increase in
BMD testing represents a true measure of how the tool
functioned in ‘real’ practice. We considered pragmatism in
the tool design because our foundational work indicated
that such tools might unintentionally disrupt the real
reason for the visit under more controlled conditions
(i.e., if a prompting mechanism was enforced for every at-
risk patient) [28]. Healthcare professionals prefer the
provision of guidance that does not interfere with usual
care [49], as confirmed by our investigation of practice
workflows across the three sites, so we deliberately de-
signed the tool to not prompt patients to complete the risk
questionnaire. This also meant that the tool was not initi-
ated during every relevant ‘at-risk’ encounter, which re-
sulted in a relatively low rate of use (16% across the three
sites). However, physicians addressed the disease manage-
ment of more than half of these patients, which indicates
that the tool has great potential to enhance care. The chal-
lenge in designing KT tools such as this one is to find the
right balance between transmitting appropriate practice
knowledge at the right time and ensuring that more ur-
gent aspects of the visit agenda (e.g., chest pain) or health
status (e.g., diabetes complication) are not disrupted, par-
ticularly in practice settings where visits are short and
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decisions.
Our positive findings also highlight several unique fea-
tures that can be considered when designing clinical de-
cision support systems such as the Op-KT tool. First,
the information that our tool delivered to physicians and
patients was customized according to the risk profile of
each individual patient. The tool functions by extracting
and analyzing risk inputs according to a guideline-based
disease management algorithm; and then deliver rele-
vant, evidence-based prompts to aid physicians in their
clinical decision making (BestPROMPT), and provide a
risk profile for patients with self-management options
tailored to their own risks (COPE). Very few existing
tools have all of these features. FRAX, a widely known
risk assessment tool, is designed to estimate individual-
ized 10-year probability of hip and major osteoporotic
fractures [50], and has been calibrated for populations in
Canada [51] and the United States [52]. It estimates the
10-year fracture risk by integrating age, gender, and
seven clinical risk factors independent of BMD [50], but
it was not designed to consider the treatment recom-
mendations that would be relevant to the risks identi-
fied, nor can it suggest tailored messages for patients to
facilitate self-management. Additionally, evidence from
many studies has shown that guidelines on their own are
not sufficient to change practice [53] and decision sup-
port tools, such as the one we created, provide potential
solutions to this challenge.
Second, our finding that patient involvement in disease
management is feasible at the point of care highlights
the untapped opportunities to improve care in primary
care settings. A recent systematic review of quality im-
provement strategies for diabetes mellitus found that
interventions targeting the disease management system
along with patient-mediated strategies improved care
[54]. Another recent analysis showed that clinical deci-
sion support systems that provide advice for patients in
addition to practitioners are more likely to succeed [55].
Lack of time is a major barrier to implementing clinical
decision support tools in family practices [56,57], so it’s
prudent to shift some of the disease management tasks
to patients. In our study, we showed that this is possible,
as patients were able to complete the RAQ in the wait-
ing room or in the examination room prior to their visit.
Involving patients in the continuum of care can facili-
tate self-management, making it easier for patients to
receive important information and to gain the skills and
confidence (self-efficacy) to deal with their illness [58].
Moreover, patient self-management may facilitate the
sustainability of an intervention by alleviating resource
burdens that might be needed to maintain continuing
use of the tool. Indeed, elderly patients are the fastest-
growing population group [59], a demographic shift thatis expected to increase the prevalence of chronic dis-
eases [60] and the need for patient self-care to support
disease management [60,61].
This study also made several contributions to the de-
velopment of complex interventions for chronic disease
where the goal is to effectively translate best evidence at
the point of care. The tool underwent substantial usability
testing before implementation [28]. Moreover, workflow
analysis preceded its roll-out in the family practice units
to optimize use of the tool. These efforts were perceived
to have been successful, because the patients who initiated
the RAQ were able to complete it rapidly (mean 3.43
minutes). Lastly, the Op-KT tool was developed from a
robust evidentiary base informed by two theoretical
frameworks (the knowledge-to-action and MRC frame-
works). These not only helped in mapping the process
for translating osteoporosis evidence into practice, they
also facilitated the selection of appropriate study designs
to answer our questions, to anticipate barriers, to evalu-
ate outcomes, and to address implementation and sus-
tainability barriers [62].
Our study had some limitations. This was a pilot
study, so our sample sizes were smaller than would be
expected if we had conducted a more rigorous random-
ized controlled trial (RCT). As a result, findings may not
be generalizable to other family practice settings or pop-
ulations. However, in ITS studies, sample size calcula-
tions are related to the estimation of the number of
observations or time points at which data are collected ra-
ther than the number of sites, physicians, and patients. As
such, we included a higher number of data points (i.e., 26
data points before and 26 data points after the introduc-
tion of the intervention) than recommended (20 data
points before/after) to ensure enough power to detect a
change and to account for threats to internal validity
[32,33]. Furthermore, data points were set closer together
(i.e., each data point represented a two-week period rather
than four weeks) to increase validity [34]. We recognize
that the ITS methodology is inherently more susceptible
to validity threats than would be a more rigorous RCT de-
sign. However, for a pilot evaluation, this methodology
was most appropriate, and we designed our study accord-
ing to rigorous ITS criteria [32,33] to help rule out alter-
native explanations of our findings. Third, the guideline
used in the study was an earlier version [30], so the rec-
ommendations are not consistent with current guidelines.
However, the tool is currently being updated to reflect
these changes. Although we planned to integrate our
tool within the PracticeSolutions system, this was not
possible because of programming and EMR proprietary
barriers. Such integration can facilitate more efficient
delivery of patient-specific decision support at the point
of care [38,57,63], and a more automated transfer of
data while preserving the accuracy of patient-reported
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electronic system could benefit clinical practice. In
addition, the majority of current practices are paper-
based, so our tool is more generalizable to these settings
now, but has great potential to be transformed into a
fully electronic tool as physician practices become in-
creasingly paperless.
Conclusions
Our multicomponent Op-KT tool significantly increased
osteoporosis disease management in three family prac-
tices. This study highlights the potential of using decision
support tools at the point of care in busy, short-visit prac-
tices to facilitate patient self-management.
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